General

• Bristol-Myers Squibb home page

• SEC 10-K Annual Financial Filing for the year 2001. Contains sales figures and patent expiration dates for the company's ten largest selling drugs, firm-level R&D figures, information on lawsuits filed against the firm, income and cost data, stock information, financial holdings, and a complete list of BMS's subsidiaries.
• Notice of 2002 Annual Meeting and Proxy Statement. Contains exececutive compensation figures, including salaries and stock options.
• CEO Charles Heimbold, Jr.'s salary and stock options from the AFL-CIO's page on executive compensation.

• Searchable database of donations (both hard and soft money) and lobbying expenses maintained by the Center for Responsive Politics.

March 7, 2003. BMS and the Federal Trade Commission reach a proposed settlement relating to antitrust claims relating to Taxol, Platinol and BuSpar. The FTC complaint states that BMS's abuse of the patent and regulatory systems protected $2 billion worth of sales annually. This cost American consumers hundreds of millions of dollars a year.

Among the allegations against BMS: paying a potential generic competitor $72.5 million to not challenge a BMS patent, abusing FDA regulations to stave off generic entry, making false statements to the FDA regarding patent listings in the orange book, "engaging in inequitable conduct" before the US patent and trademark office, and filing baseless patent infringement suits.

Statments on Proposed Settlement

• March 7, 2003. FTC press release. FTC Charges Bristol-Myers Squibb with Pattern of Abusing Government Processes to Stifle Generic Drug Competition.
• March 7, FTC report. Analysis to Aid Public Comment In the Matter of Bristol-Myers Squibb Company.
• March 7, 2003. BMS press release. Bristol-Myers Squibb Announces Agreements With State Attorneys General And Federal Trade Commission.

• March 10, 2003. John R. Wilke for the Wall Street Journal. Bristol-Myers Settles Charges of Patent-Law Abuse.
• March 8, 2003. David Ho for the Associated Press. Bristol-Myers Squibb Settles FTC Charges.
• March 7, 2003. Reuters. ristol-Myers Will Settle Antitrust Charges by U.S.

• Paclitaxel (Taxol) CPT's page on Taxol, a drug developed largely with government funds, then licensed to BMS. As of September, 2000, BMS's price was $6.09 per milligram, while foreign generic producers reported production costs of $0.07 per milligram.
• January 7, 2003. BMS press release. Bristol Myers Squibb to Settle Antitrust Litigation.
• News Stories:
  • January 8, 2003. Melody Petersen for the New York Times. Bristol-Myers Squibb to Pay $670 Million to Settle Lawsuits.
  • January 7, 2003. Associated Press. Bristol-Myers to Pay $670 Million to Settle Antitrust Accusations.
• Buspirone (BuSpar) Patent protection of this drug expired November 22, 2000. To hold off generic competition, BMS filed for patent protection for the chemical produced inside the human body when a person ingests BuSpar. This was a new legal strategy, but it could have blocked entry of generics (expected to lower the price up to 75%) until the year 2020. On March 14, a federal judge ordered the FDA to approve generic BuSpar.
  • May 30, 2002. Robert Pear for the Wall Street Journal. AARP Joins Three Lawsuits Against Large Drug Companies.
  • January 10, 2001. Gardiner Harris for the Wall Street Journal. FTC Files a Brief Against Bristol-Myers In Antitrust Suit by Generic-Drug Makers.
  • March 14, 2001. Melody Petersen in the New York Times. Judge Says Mylan Can Sell Generic Version of Bristol-Myers Drug
  • March 13, 2001. Gardiner Harris for the Wall Street Journal. Judge Permits Cheap Knockoff Of Bristol Drug.
  • December 4, 2000. Bristol Myers Block on Generic Buspirone. Brad Cameron's posting to the pharm-policy list.
  • November 22, 2000. BMS evergreen of BuSpar patent. Gardiner Harris, Wall Street Journal.
• Didanosine (ddI) This drug was invented by the NIH, and the US government holds the original patent on it (patent #4,861,759). The government licensed the drug to BMS on an exclusive basis. The NIH license to BMS has a reasonable pricing clause. For more information:
  • Expiration of BMS's exclusive license on ddI.
  • CP Tech's page on HIV/AIDS drugs developed with federal funding.
  • December 2000. Tinker Ready in Nature Medicine (Volume 6 Number 12). NIH sues BMS over missing drug royalties.
• Zerit (d4T) Includes information on U.S. government involvement in research and development, pricing, access issues, and annual sales.

• PATENT AND EXCLUSIVITY DATA FOR EVERY DRUG PRODUCED BY BRISTOL-MYERS SQUIB. Table prepared by Bruce Pokras. This information is also available in the FDA Orange Book.

Country Disputes

• South Africa Bristol-Myers Squibb is involved in a dispute over changes in South Africa's Medicines Act, which would allow greater access to medicines through compulsory licensing and parallel imports of pharmaceuticals.
• Thailand CPT page containing information on a dispute concerning the compulsory licensing of ddI in Thailand.

Philanthropy

• Bristol-Myers Foundation
• March 14, 2001. Bristol-Myers Squibb announces that "The patent for Zerit [d4T]... will be made available at no cost to treat AIDS in South Africa." On May 8, 2001 the South African treatment Action Campaign issued a statement that low cost drugs had not reached pharmacy shelves.
  • Bristol-Myers Squibb press release.
  • Treatment Access Campaign press release.
  • March 16, 2001. Letter from HealthGAP to Bristol-Myers Suibb
  • CPT page on offers of price reductions for HIV/AIDS drugs.
• Secure the Future
  • BMS site on Secure the Future
  • March 29, 2001. Christof Maletsky in the Nambian. US Drug Giant Injects N$3m Into Aids Drive. (Note: N$3million = US$372,902.42 at the 3/29/01 exchange rate of 0.12430.)
  • The Limits of 100 Million Bill Brubaker, Washington Post, December 29, 2000.
  • Bristol-Myers Squibb: Secure the Profit November 18, 1999, ACT-UP Paris.

• January 29, 2003. Susan Todd for the New Jersey Star-Ledger. Bristol-Myers to slash 113 research jobs.
• June 22, 2001. Letter from Ralph Nader and James Love to Peter Dolan, CEO of BMS. The letter lists a number of subsidies received by BMS from the US government.
• June 7, 2001. Ronald Baker, PhD. for hivandhepitis.com. Bristol-Myers Squibb Buys DuPont Pharmaceuticals and Acquires Sustiva (Efavirenz) and a Pipeline of new AIDS Drugs.
• June 7, 2001. WSJ.COM News Roundup. Bristol-Myers Clinches Deal to Acquire DuPont Drug Unit for $7.8 Billion in Cash For more info on the merger, see the BMS Press Release.

Contact Information

New York Office: Main Number
345 Park Ave
New York, NY 10154
(tel)212-546-4000
(fax)212-546-4020

New York Office: Public Affairs
Patrick Donohue 212-546-3992
Nancy Goldfarb 212-546-5107

Washington, DC Office
655 15th St NW # 300
Washington, DC 20005
(tel)202-783-0900
(fax)202-783-2308
Richard L. Thompson
V.P., Govt. Relations